FAQ: CMV Management
Frequently Asked Questions About CMV Management

Released: November 06, 2023

Atul Humar
Atul Humar, MD
Hannah Imlay
Hannah Imlay, MD, MS
Raymund Razonable
Raymund Razonable, MD

Activity

Progress
1
Course Completed

In this episode, Atul Humar, MD, FRCP(C); Hannah Imlay, MD, MS; and Raymund Razonable, MD, discuss cytomegalovirus (CMV) management strategies in solid organ transplantation recipients, including:

  • Evaluation of current data on CMV prevention in liver transplant recipients
  • Practical considerations for switching an institution’s antiviral therapy of choice for primary prophylaxis 
  • Barrier of resistance to antiviral therapies 
  • Factors to consider when deciding CMV treatment duration
  • Use of lymphocyte count to assess CMV cell–mediated immunity